As a spin-off from the EPFL, Abionic is born from a concept based on a new nanotechnology. We wanted to create revolutionary biomedical screening platform, allowing to test patients from a single drop of blood, in record time. From the very first day, we have been aware that we’ll need to raise a significant amount of money to realize our dream and bring the product on the market. In consequence, our biggest challenge was to identify the right investors profile, and to convince them to invest in Abionic. BAS has been one of the very first investors that we have been in contact with.